Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Background Treatment for stage III non‐small cell lung cancer (NSCLC) of unresectable disease mainly involves concurrent chemoradiation (CRT). Post‐CRT consolidation treatment with durvalumab is a major therapeutic advance that provides survival benefit in this group of patients. However, the perfor...

Full description

Bibliographic Details
Main Authors: Chia‐Hsun Chu, Tzu‐Hsuan Chiu, Chin‐Chou Wang, Wen‐Chen Chang, Allen Chung‐Cheng Huang, Chien‐Ying Liu, Chih‐Liang Wang, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi S. Kuo, Cheng‐Ta Yang
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Thoracic Cancer
Subjects:
Chemoradiation
consolidation
durvalumab
Online Access:https://doi.org/10.1111/1759-7714.13426

Internet

https://doi.org/10.1111/1759-7714.13426

Similar Items